Skip to content
Skip to content
← all research
STUDY

"Equity-state edge research -- Phase 3 (risk overlay)"

2026-10-04

·

Generated 2026-10-05 | frozen sleeves, walk-forward from 2010-01-01, untouched holdout >= 2023-01-01 | monthly re-selected sizing map (chosen on past only, >= 90% of base return) | PIT buckets | overlay cost 5bps on |dmult|.

#eqmom -- walk-forward OOS

overlayretsharpemaxDDdownvolCVaR5calmar
BASE+970.5%0.97-34.1%16.6%-2.08%28.42
breadth+420.7%0.84-34.1%15.0%-1.68%12.32
dispersion+292.4%0.82-21.3%12.0%-1.60%13.74
concentration+414.3%0.90-26.4%13.8%-1.63%15.69
combined+529.4%0.89-34.1%15.4%-1.85%15.51

#eqmom -- HOLDOUT

overlayretsharpemaxDDdownvolCVaR5calmar
BASE+236.6%1.49-26.0%18.3%-2.48%9.08
breadth+236.6%1.49-26.0%18.3%-2.48%9.08
dispersion+217.7%1.56-21.4%15.9%-2.16%10.18
concentration+236.6%1.49-26.0%18.3%-2.48%9.08
combined+236.6%1.49-26.0%18.3%-2.48%9.08

#flagship -- walk-forward OOS

overlayretsharpemaxDDdownvolCVaR5calmar
BASE+583.1%0.84-30.8%15.0%-1.88%18.93
breadth+476.9%0.83-30.8%15.0%-1.88%15.48
dispersion+464.6%0.82-30.8%15.0%-1.88%15.08
concentration+385.0%0.78-30.8%14.8%-1.76%12.50
combined+435.3%0.81-30.8%14.6%-1.82%14.13

#flagship -- HOLDOUT

overlayretsharpemaxDDdownvolCVaR5calmar
BASE+193.8%1.62-18.3%13.1%-1.57%10.58
breadth+193.8%1.62-18.3%13.1%-1.57%10.58
dispersion+193.8%1.62-18.3%13.1%-1.57%10.58
concentration+193.8%1.62-18.3%13.1%-1.57%10.58
combined+193.8%1.62-18.3%13.1%-1.57%10.58

#Parameter perturbation (combined overlay, eqmom walk-forward)

lookstepdSharpedMaxDDdRet
504.063.0-0.05+4.2%-518.5%
504.0126.0-0.05+4.2%-530.1%
504.0252.0-0.06+4.2%-549.6%
756.063.0-0.04-0.0%-389.7%
756.0126.0-0.08-0.0%-441.1%
756.0252.0-0.07-0.0%-431.2%
1008.063.0-0.02+6.6%-438.5%
1008.0126.0-0.03+6.6%-449.3%
1008.0252.0-0.03+6.6%-453.5%

Placebo (block-permuted state buckets, 100 reps) p = 0.920

#Phase-3 verdict

  • eqmom: walk-forward best overlay has Sharpe 0.90 vs base 0.97 and maxDD -26.4% vs -34.1%; holdout best is 1.56 vs base 1.49.

  • flagship: walk-forward best overlay has Sharpe 0.83 vs base 0.84 and maxDD -30.8% vs -30.8%; holdout best is 1.62 vs base 1.62.

  • Holdout cells meeting a naive gate (better maxDD AND Sharpe within 0.10 of base): eqmom/dispersion (Sharpe 1.56 vs 1.49, maxDD -21.4% vs -26.0%). These are single cells among ~40 tested with no multiple-testing correction, and their walk-forward counterparts are inferior; they do NOT meet the promotion bar.

  • The walk-forward overlay systematically REDUCES Sharpe and gives back large return for at best a comparable drawdown; the parameter perturbation shows the drawdown effect is unstable (flips sign with look/step), and the block-placebo p=0.92 shows the observed overlay Sharpe change is no better than a permuted/random state assignment.

  • The state features are genuine forward-RISK predictors (Phase 1/2) but do NOT produce a promotable exposure overlay: the frozen sleeves already carry their own risk controls (vol target, stops, credit/VIX gates), so an exogenous de-risk mostly subtracts return.

Recommendation: DO NOT PURSUE the overlay. Equity-state is informative as a risk monitor / research diagnostic, not as a tradeable sizing signal for these sleeves. No production change.

All trading described is paper (simulated). Not investment advice.

← all research